Welcome to Bertech Pharma.
We are dedicated to advancing colorectal cancer diagnostics and treatments.
Bertech Pharma Ltd. is a privately-held biotechnology company founded in 2008 focused on the development of innovative products to advance the diagnosis and treatment of colorectal cancer.
Bertech’s goal is to advance diagnosis, assessment and treatment options for clinicians, which will improve outcomes for patients. Development of our leading edge biomarker assays and our new treatment compounds will increase early detection and improve treatment selection and assessment.
Latest News >
- March 11, 2020 — Bertech’s Pivotal Trial Validates Blood Test for Colorectal Cancer
- February 26, 2013 — Dr. David Dureck joins Bertech Pharma’s Scientific Board of Advisors
- September 06, 2012 — Dr. David Evans and Dr. Randall Johnston join Bertech Pharma’s Scientific Board of Advisors